Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 35K | 35K | 0 |
| Gross Profit | 0 | -168K | 27K | 27K | -4K |
| Operating Income | -788K | -2M | -2M | -2M | -2M |
| EBITDA | -788K | -2M | -2M | -2M | -2M |
| Net Income | -1M | -2M | -2M | -2M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.028
-6.67% today
1Y Change
+73.33%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Qscreen Ai Inc. (PMEDF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.03 and up 73.3% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +43.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +43.9%, free cash flow +97.8% with operating margin 0.0% and ROIC 118.8%. Stock Foundry combines PMEDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMEDF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PMEDF Max Drawdown
-62.69%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PMEDF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$1.6M
+16.0% YoY
Free Cash Flow
-$2.0M
-187.3% YoY
Revenue Growth
+0.0%
EPS Growth
+43.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 35K | 35K | 0 |
| Gross Profit | 0 | -168K | 27K | 27K | -4K |
| Operating Income | -788K | -2M | -2M | -2M | -2M |
| EBITDA | -788K | -2M | -2M | -2M | -2M |
| Net Income | -1M | -2M | -2M | -2M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 37K | 79K | 211K | 480K |
| Total Assets | 132K | 481K | 718K | 718K | 1M |
| Total Liabilities | 1M | 625K | 871K | 871K | 350K |
| Shareholder Equity | -1M | -144K | -153K | -153K | 887K |
| Total Debt | 0 | 0 | 38K | 38K | 0 |
| Net Debt | 0 | -37K | -41K | -173K | -480K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
-186.8% YoY
Capital Expenditures
418K
-189.0% YoY
Free Cash Flow
2M
-187.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
123.6%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.